TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial on Women's Substance Abuse Treatment
Brief Summary: The purpose of this study is to examine the efficacy of a gender-focused addiction treatment model (A Woman's Path to Recovery) versus a non-gender focused addiction treatment model (12-Step Facilitation) in a sample of women Veterans with substance use disorder.


Options:
A: Arm Label: A Woman's Path to Recovery (WPR); Type: EXPERIMENTAL; Interventions: Behavioral: A Woman's Path to Recovery | Arm Label: 12-Step Facilitation (TSF); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: 12-Step Facilitation | Intervention Type: BEHAVIORAL; Name: A Woman's Path to Recovery; Assigned to Arm(s): A Woman's Path to Recovery (WPR) | Intervention Type: BEHAVIORAL; Name: 12-Step Facilitation; Assigned to Arm(s): 12-Step Facilitation (TSF)
B: Arm Label: IPS Only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Individual Placement and Support (IPS) supported employment | Arm Label: IPS Plus Wage Supplement; Type: EXPERIMENTAL; Interventions: Behavioral: Abstinence-contingent wage supplements, Behavioral: Individual Placement and Support (IPS) supported employment | Intervention Type: BEHAVIORAL; Name: Abstinence-contingent wage supplements; Assigned to Arm(s): IPS Plus Wage Supplement | Intervention Type: BEHAVIORAL; Name: Individual Placement and Support (IPS) supported employment; Assigned to Arm(s): IPS Only, IPS Plus Wage Supplement
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Disulfiram; Type: ACTIVE_COMPARATOR; Interventions: Drug: disulfiram | Arm Label: Placebo plus Contingency Management; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Placebo plus Contingency Management | Arm Label: Disulfiram plus Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Drug: Disulfiram plus Contingency Management | Intervention Type: DRUG; Name: disulfiram; Assigned to Arm(s): Disulfiram | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Placebo plus Contingency Management; Assigned to Arm(s): Placebo plus Contingency Management | Intervention Type: DRUG; Name: Disulfiram plus Contingency Management; Assigned to Arm(s): Disulfiram plus Contingency Management
D: Arm Label: cognitive function rehabilitation group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: cognitive function rehabilitation and bias modification | Arm Label: cognitive bias modification group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: cognitive function rehabilitation and bias modification | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: cognitive function rehabilitation and bias modification; Assigned to Arm(s): cognitive bias modification group, cognitive function rehabilitation group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Does Prophylaxis With Macrobid Reduce the Incidence of Urinary Tract Infection in Patients Who Receive a Sub-Urethral Sling for the Treatment of Stress Urinary Incontinence: Randomized, Double Blinded Placebo Controlled Clinical Trial
Brief Summary: This project will determine whether post-operative prophylaxis with macrobid will decrease the incidence of postoperative urinary tract infection in women receiving sub-urethral slings for the treatment of urinary incontinence.


Options:
A: Arm Label: Nitrofurantoin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nitrofurantoin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Nitrofurantoin; Assigned to Arm(s): Nitrofurantoin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: BMI <30; Type: N/A; Interventions: N/A | Arm Label: BMI 30-39; Type: N/A; Interventions: N/A | Arm Label: BMI >40; Type: N/A; Interventions: N/A
C: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Drug: Nitrofurantoin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Nitrofurantoin; Assigned to Arm(s): Treatment | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Ajust sling; Type: EXPERIMENTAL; Interventions: Procedure: Ajust system, Procedure: TVT/TVT-O | Arm Label: TVT/TVT-O, polypropylne slings; Type: EXPERIMENTAL; Interventions: Procedure: Ajust system, Procedure: TVT/TVT-O | Intervention Type: PROCEDURE; Name: Ajust system; Assigned to Arm(s): Ajust sling, TVT/TVT-O, polypropylne slings | Intervention Type: PROCEDURE; Name: TVT/TVT-O; Assigned to Arm(s): Ajust sling, TVT/TVT-O, polypropylne slings

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Forced-dose Titration, Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Adolescents Aged 13-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)
Brief Summary: The study will evaluate the efficacy of LDX treatment group compared to placebo on the change from Baseline ADHD-RS-IV score at endpoint.


Options:
A: Arm Label: Methylphenidate, Dexamphetamine, Placebo; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate, Drug: Placebo, Drug: Dextroamphetamine | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Methylphenidate, Dexamphetamine, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Methylphenidate, Dexamphetamine, Placebo | Intervention Type: DRUG; Name: Dextroamphetamine; Assigned to Arm(s): Methylphenidate, Dexamphetamine, Placebo
B: Arm Label: Lisdexamfetamine Dimesylate (LDX) 30 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: LDX 30 mg | Arm Label: LDX 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: LDX 50 mg | Arm Label: LDX 70 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: LDX 70 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: LDX 30 mg; Assigned to Arm(s): Lisdexamfetamine Dimesylate (LDX) 30 mg | Intervention Type: DRUG; Name: LDX 50 mg; Assigned to Arm(s): LDX 50 mg | Intervention Type: DRUG; Name: LDX 70 mg; Assigned to Arm(s): LDX 70 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Lisdexamfetamine Dimesylate (LDX); Type: EXPERIMENTAL; Interventions: Drug: Lisdexamfetamine Dimesylate (LDX) | Arm Label: Methylphenidate Hydrochloride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lisdexamfetamine Dimesylate (LDX); Assigned to Arm(s): Lisdexamfetamine Dimesylate (LDX) | Intervention Type: DRUG; Name: Methylphenidate Hydrochloride; Assigned to Arm(s): Methylphenidate Hydrochloride | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Lisdexamfetamine Dimesylate (LDX, SPD489); Type: ACTIVE_COMPARATOR; Interventions: Drug: LDX | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: LDX; Assigned to Arm(s): Lisdexamfetamine Dimesylate (LDX, SPD489) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intra-Nasal vs. Intra-Venous Lorazepam for Control of Acute Seizures in Children: Prospective Open Labeled Randomized Equivalence Trial
Brief Summary: Status epilepticus (SE) is a common pediatric emergency which is potentially life-threatening and requires rapid termination. Early and effective treatment is essential to prevent the morbidity and mortality associated with prolonged convulsive SE. Lorazepam is the standard of care for control of SE when administered by intra-venous (IV) route. The investigators intend to compare efficacy and adverse effect profile of intra-nasal vs. intravenous routes of administration of lorazepam. In resource poor settings, sometimes trained personnel or appropriate equipment for intra-venous cannulation is not available. Alternate routes of administration, if shown equivalent to conventional IV route, will be very useful in such settings or for out of hospital management of seizures in children.


Options:
A: Arm Label: Cohort 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: lorazepam or diazepam | Arm Label: Cohort 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: lorazepam or diazepam | Intervention Type: DRUG; Name: lorazepam or diazepam; Assigned to Arm(s): Cohort 1, Cohort 2
B: Arm Label: Intramuscular (IM) anticonvulsant; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intramuscular route of active treatment | Arm Label: Intravenous (IV) anticonvulsant; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous route of active treatment | Intervention Type: DRUG; Name: Intramuscular route of active treatment; Assigned to Arm(s): Intramuscular (IM) anticonvulsant | Intervention Type: DRUG; Name: Intravenous route of active treatment; Assigned to Arm(s): Intravenous (IV) anticonvulsant
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Lorazepam | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lorazepam | Intervention Type: DRUG; Name: Lorazepam; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Lorazepam; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: intranasal lorazepam; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: intramuscular paraldehyde; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 3 Doses of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Brief Summary: The purpose of this study is to determine the effectiveness and safety of vortioxetine, once daily (QD), in patients with Major Depressive Disorder.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Vortioxetine 10 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine | Arm Label: Vortioxetine 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine | Intervention Type: DRUG; Name: Vortioxetine; Assigned to Arm(s): Vortioxetine 10 mg, Vortioxetine 20 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Vortioxetine (Lu AA21004) 5 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine (Lu AA21004) | Arm Label: Vortioxetine (Lu AA21004) 10 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine (Lu AA21004) | Arm Label: Venlafaxine XL 225 mg; Type: OTHER; Interventions: Drug: Venlafaxine XL | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Vortioxetine (Lu AA21004); Assigned to Arm(s): Vortioxetine (Lu AA21004) 10 mg, Vortioxetine (Lu AA21004) 5 mg | Intervention Type: DRUG; Name: Venlafaxine XL; Assigned to Arm(s): Venlafaxine XL 225 mg
C: Arm Label: Vortioxetine 1 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine | Arm Label: Vortioxetine 5 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine | Arm Label: Vortioxetine 10 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vortioxetine; Assigned to Arm(s): Vortioxetine 1 mg, Vortioxetine 10 mg, Vortioxetine 5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Vortioxetine: 15 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine (Lu AA21004) | Arm Label: Vortioxetine: 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine (Lu AA21004) | Arm Label: Duloxetine: 60 mg; Type: OTHER; Interventions: Drug: Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Vortioxetine (Lu AA21004); Assigned to Arm(s): Vortioxetine: 15 mg, Vortioxetine: 20 mg | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine: 60 mg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet
Brief Summary: Evaluate the efficacy and safety of a 16-week course of Humira (adalimumab) compared to placebo in adults with chronic plaque psoriasis of the hands and/or feet and the sustainability of response for 12 additional weeks.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 50 mg etanercept; Type: ACTIVE_COMPARATOR; Interventions: Drug: 50 mg etanercept | Arm Label: 80 mg ixekizumab Dosing Regimen 2; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab | Arm Label: 80 mg ixekizumab Dosing Regimen 1; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: 50 mg etanercept; Assigned to Arm(s): 50 mg etanercept | Intervention Type: DRUG; Name: 80 mg ixekizumab; Assigned to Arm(s): 80 mg ixekizumab Dosing Regimen 1, 80 mg ixekizumab Dosing Regimen 2
B: Arm Label: Placebo Comparator: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Voclosporin 0.2 mg/kg po BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: voclosporin | Arm Label: Voclosporin 0.3 mg/kg po BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: voclosporin | Arm Label: Voclosporin 0.4 mg/kg po BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: voclosporin | Intervention Type: DRUG; Name: voclosporin; Assigned to Arm(s): Voclosporin 0.2 mg/kg po BID, Voclosporin 0.3 mg/kg po BID, Voclosporin 0.4 mg/kg po BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Comparator: 1
C: Arm Label: Placebo/Adalimumab; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Adalimumab | Arm Label: Adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo/Adalimumab | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Adalimumab, Placebo/Adalimumab
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Biological: ABT-874 | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Biological: etanercept | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: BIOLOGICAL; Name: ABT-874; Assigned to Arm(s): A | Intervention Type: BIOLOGICAL; Name: etanercept; Assigned to Arm(s): B | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): C

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet
Brief Summary: Evaluate the efficacy and safety of a 16-week course of Humira (adalimumab) compared to placebo in adults with chronic plaque psoriasis of the hands and/or feet and the sustainability of response for 12 additional weeks.


Options:
A: Arm Label: Group 1: Approved q12w maintenance regimen; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 45 mg, Drug: Ustekinumab 90 mg, Drug: Placebo | Arm Label: Group 2: Subject-tailored fixed-interval maintenance regimen; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 45 mg, Drug: Ustekinumab 90 mg, Drug: Placebo | Intervention Type: DRUG; Name: Ustekinumab 45 mg; Assigned to Arm(s): Group 1: Approved q12w maintenance regimen, Group 2: Subject-tailored fixed-interval maintenance regimen | Intervention Type: DRUG; Name: Ustekinumab 90 mg; Assigned to Arm(s): Group 1: Approved q12w maintenance regimen, Group 2: Subject-tailored fixed-interval maintenance regimen | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 1: Approved q12w maintenance regimen, Group 2: Subject-tailored fixed-interval maintenance regimen
B: Arm Label: Single-Arm, open-label extension trial; Type: OTHER; Interventions: Drug: Adalimumab | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Single-Arm, open-label extension trial
C: Arm Label: AIN457 150 mg; Type: EXPERIMENTAL; Interventions: Drug: secukinumab 150 mg, Drug: placebo to secukinumab 150 mg | Arm Label: AIN457 300 mg; Type: EXPERIMENTAL; Interventions: Drug: secukinumab 150 mg, Drug: placebo to secukinumab 150 mg | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo to secukinumab 150 mg | Arm Label: AIN457 150mg from Placebo; Type: EXPERIMENTAL; Interventions: Drug: secukinumab 150 mg, Drug: placebo to secukinumab 150 mg | Arm Label: AIN457 300mg from Placebo; Type: EXPERIMENTAL; Interventions: Drug: secukinumab 150 mg, Drug: placebo to secukinumab 150 mg | Intervention Type: DRUG; Name: secukinumab 150 mg; Assigned to Arm(s): AIN457 150 mg, AIN457 150mg from Placebo, AIN457 300 mg, AIN457 300mg from Placebo | Intervention Type: DRUG; Name: placebo to secukinumab 150 mg; Assigned to Arm(s): AIN457 150 mg, AIN457 150mg from Placebo, AIN457 300 mg, AIN457 300mg from Placebo, placebo
D: Arm Label: Placebo/Adalimumab; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Adalimumab | Arm Label: Adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo/Adalimumab | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Adalimumab, Placebo/Adalimumab

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet
Brief Summary: Evaluate the efficacy and safety of a 16-week course of Humira (adalimumab) compared to placebo in adults with chronic plaque psoriasis of the hands and/or feet and the sustainability of response for 12 additional weeks.


Options:
A: Arm Label: Ixekizumab; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab | Arm Label: Fumaric Acid Esters; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fumaric Acid Esters, Drug: Ixekizumab | Arm Label: Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Ixekizumab | Intervention Type: DRUG; Name: Fumaric Acid Esters; Assigned to Arm(s): Fumaric Acid Esters | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Methotrexate | Intervention Type: DRUG; Name: Ixekizumab; Assigned to Arm(s): Fumaric Acid Esters, Ixekizumab, Methotrexate
B: Intervention Type: DRUG; Name: adalimumab; Assigned to Arm(s): N/A
C: Arm Label: Placebo/Adalimumab; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Adalimumab | Arm Label: Adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo/Adalimumab | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Adalimumab, Placebo/Adalimumab
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Biological: ABT-874 | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Biological: etanercept | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: BIOLOGICAL; Name: ABT-874; Assigned to Arm(s): A | Intervention Type: BIOLOGICAL; Name: etanercept; Assigned to Arm(s): B | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): C

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet
Brief Summary: Evaluate the efficacy and safety of a 16-week course of Humira (adalimumab) compared to placebo in adults with chronic plaque psoriasis of the hands and/or feet and the sustainability of response for 12 additional weeks.


Options:
A: Arm Label: Bimekizumab cohort; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab | Arm Label: Ustekinumab cohort; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab, Other: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bimekizumab, Other: Placebo | Intervention Type: DRUG; Name: Bimekizumab; Assigned to Arm(s): Bimekizumab cohort, Placebo | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Ustekinumab cohort | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo, Ustekinumab cohort
B: Arm Label: ABP 501; Type: EXPERIMENTAL; Interventions: Biological: ABP 501 | Arm Label: Adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Adalimumab | Intervention Type: BIOLOGICAL; Name: ABP 501; Assigned to Arm(s): ABP 501
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: CZP 200 mg; Type: EXPERIMENTAL; Interventions: Other: Placebo, Drug: Certolizumab Pegol | Arm Label: CZP 400 mg; Type: EXPERIMENTAL; Interventions: Drug: Certolizumab Pegol | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): CZP 200 mg, Placebo | Intervention Type: DRUG; Name: Certolizumab Pegol; Assigned to Arm(s): CZP 200 mg, CZP 400 mg
D: Arm Label: Placebo/Adalimumab; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Adalimumab | Arm Label: Adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo/Adalimumab | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Adalimumab, Placebo/Adalimumab

Answer: D